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66 Poster Session Irender SP cells susceptible to T cell mediated destruction indicating
that T cell therapy may have a powerful effect on drug resistant tu-
mor cells when used as adjunct therapy.178
IMPROVED SURVIVAL FOR PATIENTS UNDERGOING AUTOLOGOUS
STEM CELL TRANSPLANT IN FIRST OR LATER REMISSION FOR PRIMARY
CNS LYMPHOMA
Johnston, P.B., O’Neill, B.P., Ansell, S.M., Inwards, D.J., Porrata, L.F.,
Micallef, I.N.M. Mayo Clinic, Rochester, MN.
Background: Survival for patients with primary CNS lymphoma
(PCNSL), in general, is poor with patients requiring frequent che-
motherapy treatments or receiving whole-brain radiation therapy,
which can potentially result in significant neurologic decline and
dementia. Because of the improved survival of high risk patients
with aggressive lymphoma undergoing autologous stem cell trans-
plant (ASCT), we began ASCT for patients with PCNSL in first
or later remission with chemotherapy sensitive disease.We now up-
date the outcomes of patients who have had at least 100 day follow
up post ASCT. Baseline Characteristics: Between June, 2000 and
March, 2007, 16 patients underwent ASCT for PCNSL. Median
age at transplant was 50 years old (range 30–67). Median number
of prior treatments 2 (range 1–3). Median time from diagnosis to
transplant was 7.5 months (range 2.9 to 75.8). Median International
Extranodal Working Study Group Prognostic Score: 2 (range 0–3).
Disease status at transplant: First CR 6 patients, later CR or PR 10
patients. Median follow up from diagnosis was 45 months.Results:
Sixteen patients underwent ASCT for PCNSL and have aminimum
of 100 days follow-up. All patients received BEAM conditioning.
Median follow up post-transplant was 32 months (range 3–85
months). Eight patients have relapsed at amedian of 217 days (range
40–1349). Of the patients who relapsed, two have died of disease
progression and the remaining five are alive after additional therapy.
Median overall survival from transplant has not been reached.
Three year overall and event free survival from transplant are
82% and 53%, respectively. Median progression free survival
from BMT was 45 months. Overall survival from diagnosis at 5
years was 83%.Conclusions: Although limited by patient selection
and retrospective biases, this review suggests that ASCT for
PCNSL demonstrates improved overall survival when compared
to historical controls with similar PCNSL Prognostic Scores (2
year survival for patients from diagnosis with PS 2–3 was 48% in
a prior published study). ASCT in first remission in patients with
PCNSL appears promising and may limit the need for additional
therapy which can be myelosuppressive or result in neurologic de-
cline, secondary to radiation therapy, in patients who are appropri-
ate candidates.179
ALLOGENEIC STEM CELL TRANSPLANTATION FOR POST-AUTOLOGOUS
STEM CELL TRANSPLANT RELAPSE IN HODGKIN LYMPHOMA: EXPERI-
ENCE AT A SINGLE CENTER
Oliva, J.L., Kelly, J.L., Liesveld, J.L., Becker, M.W., Phillips, G.L.,
Sensenig, E., Constine, L., Bernstein, S.H., Fisher, R.I.,
Friedberg, J.W. University of Rochester, Rochester, NY.
Autologous stem cell transplantation (ASCT) is the standard of
care for relapsed or refractory Hodgkin Lymphoma (HL) and has
been associated with long-term survival rates of approximately
40%. Data regarding post-ASCT HL relapse are sparse, particu-
larly with regard to subsequent allogeneic stem cell transplantation
(allo SCT). To explore the impact of allo SCT on post-ASCT re-
lapsed HL, we evaluated all adult cases from mid 1992 to mid
2007. Primary objectives of this descriptive retrospective study
were to determine transplant-related characteristics, survival and
the incidence of GVHD. Fifteen cases (7 females, 8 males) met
study entry criteria. Histology included NS (14) and MC (1); 5
had primary refractory HL. All initially received ABVD and salvage
regimens varied. BEAM was the most commonly administeredASCT conditioning regimen and 9 received post-ASCT radiation.
Median time to post-ASCT relapse was 8 months (range 1–49).
Pre-allo SCT disease status was: CR (2); sensitive (6); stable (5);
missing (2). Median age at allo SCT was 34.4 years (range 20.0–
54.3). Reduced intensity (RI) and ablative regimens were adminis-
tered in 13 and 2 cases, respectively. RI regimens comprised 3major
categories: fludarabine and melphalan (7); pentostatin, TBI and
photopheresis (4); other (2). Donors were siblings (6) or unrelated
volunteers (9); 5 donor/recipient pairs were HLA mismatched.
GVHD prophylaxis included: tacrolimus or CSA plusMMF (7); ta-
crolimus and sirolimus (5); tacrolimus or CSA with mini-metho-
trexate (3). Seven patients are deceased with a median survival
post-allo SCT of 9 months (range 1–18). HL was the primary cause
of death for 4. Of the 8 surviving (median follow-up 8.5 months;
range 2–19), 2 have relapsed HL treated with further radiation or
donor leukocytes. Overall, 60% were treated for acute or chronic
GVHD and 4 of those surviving have extensive chronic GVHD.
Of these 4, 3 remain in remission more than 1-year after allo SCT.
Conclusions: Follow-up, survival, and complications in HL re-
lapsed after ASCT are largely under-reported in the literature. Pre-
vious evidence suggests a high TRM forHL after allo SCTutilizing
traditional ablative regimens, however, outcomes are lesser known
in a new era of RI options. There is literature to suggest that allo
SCT may afford a GV-HL effect that is potentially curative, but
data are currently lacking to support a standard treatment approach.
Novel approaches and/or therapeutic clinical trials are needed.180
A SUCCESSFUL TREATMENT STRATEGY FOR PATIENTS WITH T-NHL:
ALLOGENEIC TRANSPLANTATION AFTER BEAM-ALEMTUZUMAB
CONDITIONING
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For patients with relapsed or refractory T-cell lymphomas the
prognosis is grim and no standard treatment strategy exists. In ad-
dition, mature T/NK-cell-lymphomas are an infrequent and het-
erogeneous group of lymphoid tumors. Ten patients with
relapsed T-cell Non-Hodgkin’s lymphoma (NHL) were treated
with allogeneic stem cell transplantation (SCT) after 1 to 2 cycles
of CLAEG (cladribine, cytarabine, etoposide/etopophos and G-
CSF) induction therapy immediately followed by conditioning
with BEAM (carmustine, cytarabine, etoposid/etopophos, melpha-
lan) combined with alemtuzumab (Campath-1H). The following
subtypes were included: 5 peripheral T-cell lymphomas (not other-
wise specified), 2 angioimmunoblastic, 1 ALK negative anaplastic
large cell, 1 extranodal NK/nasal type and 1 enteropathy-type T-
cell lymphoma. All patients had at least 2 different treatment regi-
mens previously. After 1 to 2 cycles of induction chemotherapy
with CLAEG, one patient achieved a CR, 6 patients a PR and 3
had SD. Conditioning with BEAM combined with alemtuzumab
was well tolerated. Seven patients received peripheral blood stem
cells (PBSC) from HLA-identical unrelated donors and 2 from
matched sibling donors, 1 patient received bone marrow from an
HLA one-allele mismatched unrelated donor. Engraftment was
rapid and the treatment well tolerated. There were 4 cases of grade
4 mucositis, 2 cases of sepsis in neutropenia, and 1 case of grade IV
liver toxicity. Prophylaxis for graft-versus-host disease (GvHD)
consisted of cyclosporine A and MTX or mycophenolate mofetil.
No grade III or IV acute GvHD was seen and only 3 patients pre-
sented with grade II GvHD. Two patients experienced limited
chronic GvHD. Asymptomatic CMV reactivation was found in 4
cases and all were treated successfully. Late infections occurred in
four patients, including CMV infection, viral enteritis, aspergillus
pneumonia and streptococcal sepsis. All patients achieved a CR af-
ter allogeneic transplantation. Currently, 3 patients have relapsed.
One patient died in CR on day 233 post transplantation due to as-
piration pneumonia caused by non-malignant bowel stenosis. All
other patients remained in CR for up to 261 months. This treat-
ment approach with CLAEG induction followed by conditioning
with BEAM combined with alemtuzumab shows a surprisingly
good outcome in a group of T-cell NHL patients with a very
poor prognosis. Allogeneic SCT with this strategy seems to be
a promising therapeutic option for these patients.
